Xencor Inc (NASDAQ:XNCR) insider John J. Kuch sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $41.27, for a total value of $1,650,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NASDAQ XNCR traded down $0.30 during trading hours on Friday, reaching $38.49. 69,257 shares of the stock traded hands, compared to its average volume of 392,512. The company has a market capitalization of $2.21 billion, a P/E ratio of -29.38 and a beta of 1.39. The company has a quick ratio of 8.27, a current ratio of 8.27 and a debt-to-equity ratio of 0.02. Xencor Inc has a 52-week low of $27.75 and a 52-week high of $48.38. The company’s 50-day simple moving average is $42.69 and its two-hundred day simple moving average is $35.38.
Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.15. The company had revenue of $19.49 million for the quarter, compared to analysts’ expectations of $7.58 million. Xencor had a return on equity of 8.40% and a net margin of 28.46%. As a group, sell-side analysts forecast that Xencor Inc will post 0.05 earnings per share for the current fiscal year.
Several research firms have weighed in on XNCR. Leerink Swann set a $52.00 price target on Xencor and gave the company a “buy” rating in a report on Wednesday, August 7th. Canaccord Genuity raised their price target on Xencor from $45.00 to $52.00 and gave the company a “buy” rating in a report on Thursday, August 8th. ValuEngine raised Xencor from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 2nd. Guggenheim cut Xencor from a “buy” rating to a “neutral” rating in a report on Wednesday, August 7th. Finally, Mizuho reaffirmed a “buy” rating and issued a $52.00 price target on shares of Xencor in a report on Monday, July 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $45.57.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Read More: Discount Rate
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.